• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Fusion Pharmaceuticals Acquires IPN-1087

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    Q BioMed Inks Strontium89 Supply Pact

    PCI Pharma Services Appoints SVP, CFO
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WuXi AppTec Completes OXGENE Acquisition

    Celonic Group Announces Plans for New Facility in Switzerland

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    WuXi AppTec Completes OXGENE Acquisition

    Live Webinar - Formulation Strategies for Poorly Soluble Molecules

    Celonic Group Announces Plans for New Facility in Switzerland
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    PCI Pharma Services

    Baxter BioPharma Solutions

    Adare Pharma Solutions

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Adare Pharma Solutions

    Emergent BioSolutions

    Reed-Lane

    Syngene

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Biopharma Contract Manufacturing: Robust Growth Ahead

    The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.

    Biopharma Contract Manufacturing: Robust Growth Ahead
    Biopharma Contract Manufacturing: Robust Growth Ahead
    Figure A. Biopharmaceutical Contract Manufacturing Capacity Utilization Rates
    Biopharma Contract Manufacturing: Robust Growth Ahead
    Figure B. CMO Capacity Utilization Rate Distribution
    Biopharma Contract Manufacturing: Robust Growth Ahead
    Figure C. Top Outsourcing Decision Factors
    William Downey, HighTech Business Decisions11.17.20
    The biopharmaceutical contract manufacturing market continues its upward trajectory as pharmaceutical and biotechnology companies increase their spending for outsourced services. This growth results from the expanded use of biopharmaceuticals, new biopharmaceutical approvals and new biopharmaceutical development programs. This article reviews the biopharmaceutical contract manufacturing market, capacity utilization and additions, outsourcing decision factors, and selected industry trends.

    The information presented in this article draws from HighTech Business Decisions’ latest report, “Biopharmaceutical Contract Manufacturing 2020: New Demand and Expanded Services.”1 This report is based on primary research from senior-level executives and scientists at pharmaceutical and biotechnology companies plus executives at contract manufacturing organizations. For purposes of our article, HighTech Business Decisions defines biopharmaceuticals as complex molecules expressed through the genetically manipulated living cells or organisms used for therapeutics or vaccines.

    Market growth
    The biopharmaceutical contract manufacturing market will reach $6.3 billion in 2020. The market will continue to grow as pharmaceutical and biotechnology companies increase their spending for outsourced services. The expected increase in outsourced spending is consistent with the biopharmaceutical contract manufacturing organizations’ expectations. The biopharmaceutical contract manufacturing organizations (CMOs) expect double-digit market growth over the next three years, with smaller CMOs expecting higher growth rates compared to larger CMOs. The CMOs gave several reasons for their optimistic outlook. These reasons include an increase in small, well-funded virtual biotechnology companies, higher demand for production services supporting cell and gene therapies, and higher growth in Asia. The market to support cell and gene therapies is expected to grow at twice the overall industry growth rate. Over the next few years, monoclonal antibodies (mAbs) will account for half the molecules entering the clinical pipeline, including standard mAbs and multi-specific mAbs. Molecules related to cell and gene therapies, including viral vectors, will account for 23% of the molecules entering the clinical pipeline. All CMOs offer production, development and ancillary services. Overall, production accounts for 80% of the market. Development and ancillary services (e.g., testing, cell banking, and regulatory support) account for roughly 20% of the market. The mix between production and all other services has remained steady over the past several years.
    Below are selected comments from CMOs regarding the demand for biopharmaceutical contract manufacturing:
    • “The demand in the industry for microbial fermentation and mammalian cell culture outsourced services has seen both increases in the last year: demand is up, but is due only to existing clients who are growing business.”  —CMO Respondent
    • “For mammalian cell culture outsourced services, industry demand has increased by approximately 10% in the last 12 months.”  —CMO Respondent
    • “Within the past 12 months, speaking only of mammalian cell culture outsourced services, the industry has seen an increase in demand for capacity from an increasing number of small virtual companies.”  —CMO Respondent
    • “I’m not aware of specific numbers for microbial, but mammalian is growing more than microbial. Capacity needs for mammalian has gone up 20-30% in the last year.”  —CMO Respondent
    • “[Demand] has changed, there are more microbial projects. Microbial is increasing for nucleic acid projects but for recombinant proteins too. Recombinant proteins were all mammalian, now they are going back to microbial.”  —CMO Respondent
    • “In the brave new world of gene therapy, I think we’ll see the two starting to meet. Anything you plan to do with e.g., AAV or Lentivirus will require several batches of microbial fermentation to get GMP plasmids. That is currently eating a significant amount of microbial fermentation capacity. In the past, people were trying to be more efficient and switch into prokaryotic systems products that had been made in eukaryotic systems. But now, the main driver for microbial growth is plasmids for gene therapy applications.”  —CMO Respondent

    Capacity utilization rates
    In 2020, the industry capacity utilization rate is 76%. In a reverse from earlier trends, industry capacity utilization is slightly lower this year (see Figure A). While this is a decrease from prior years, it is higher than the historical average, and slightly higher than the normal manufacturing capacity utilization rate of 75%.

    Although this year’s capacity utilization is lower, capacity utilization varies between individual CMOs and production processes. This results in a bimodal distribution of CMO capacity utilization rates (see Figure B). From our study, 44% of the responses report capacity utilization at 80% or higher, while slightly more than one-third of the responses report capacity utilization below 50%. Capacity utilization among the CMOs varies depending on CMO size and process technology. As a group, capacity utilization is higher for the larger CMOs and lower for the smaller CMOs. The lower capacity utilization reported by the smaller CMOs is consistent with their expectations of higher than average growth over the next three years. In addition, capacity utilization is higher for mammalian cell culture processes compared to microbial fermentation processes.

    Over the past three years, many CMOs have added capacity either by constructing new facilities or acquiring biomanufacturing facilities from pharmaceutical and biotechnology companies. Additionally, CMOs are also adding capacity at smaller scales through their investment in single-use bioreactors. Single-use bioreactor capacity is now widely accepted, and single-use bioreactors appear to be the preferred production mode for biopharmaceuticals that target smaller patient populations.

    New capacity additions
    Over the next three years, total capacity will increase 60% as CMOs invest to meet future demand. Most of this new capacity supports mammalian cell culture production. Given these expansion plans, capacity utilization will remain in the low 70% range throughout the forecast period. On top of adding production capacity, the CMOs are also investing in other services to meet future client needs. The CMOs are planning major investments in cell and gene therapy production capacity, analytic capabilities, new research centers, and productivity and quality enhancements. The productivity and quality enhancements include continuous manufacturing, perfusion systems, and tangential flow filtration and membrane technologies.

    Decision factors to outsource
    Collectively, the decisions made by the pharmaceutical and biotechnology companies to outsource production directly affect the biopharmaceutical contract manufacturing market. This analysis divides the CMOs’ customers between a) companies with no in-house biomanufacturing (“virtual companies”) and b) companies with in-house biomanufacturing. For virtual companies, the decision to outsource all production is generally part of its overall corporate strategy. Most virtual companies lack the resources or product offerings to justify owning a manufacturing facility. On the other hand, the companies with biomanufacturing sites or who have the resources to build in-house capacity have adopted various manufacturing strategies depending on their specific situation or strategy. These customers evaluate several factors when deciding to outsource production. From our discussions with the biomanufacturing director respondents, their companies consider the following factors in their outsourcing decisions: capacity, timeline, cost, capability, product strategy and supply chain security (see Figure C).

    The majority of respondents consider capacity a key factor in their decision to outsource production. Many of these respondents outsource production to access more capacity when production requirements exceed in-house capacity. Many times, the factors in the outsourcing decision process are interrelated. For example, the customer may lack certain manufacturing capabilities (e.g., cGMP production), and will outsource production to access the CMOs capacity and capability. Furthermore, the decision to outsource for the purpose of accessing more capacity often results from a cost analysis. The cost analysis balances in-house capacity against production requirements to determine the most efficient resource use. Related to capacity availability are expected project timelines that will influence the outsourcing decision. Timelines have multiple aspects depending on the specific situation faced by the biotechnology company. If the biotechnology company’s in-house capacity is fully utilized, then CMOs may be able to ramp up production faster than the time required to install additional capacity. On the other hand, a few respondents noted that it is faster to make product in-house than to outsource production to a CMO.

    Below are selected comments from pharmaceutical and biotechnology companies regarding the top three factors they consider when deciding to outsource:
    • “We are a virtual company.  With our limited funds, it is more efficient to outsource than build our own facility. It helps that there is more CMO capacity available near us now than there has been in the past.  I don’t expect we would build in the future.  We are more likely to out-license our molecule.”  —Pharma/Biotech Respondent
    • “The top three factors that we consider when deciding whether to outsource or produce in-house are flexibility in our manufacturing, cost and timeline of the project.”  —Pharma/Biotech Respondent
    • “Capacity as in available slots, timeline, and volume as in how much final volume produced in kilograms per unit are the top three factors we consider when deciding whether to outsource or manufacture in-house.”  —Pharma/Biotech Respondent
    • “We outsource to augment our current capacity.  It is less expensive for us to manufacture in-house, but expansion requires a long-term commitment and outsourcing to a CMO provides a stopgap until we are confident a product will be successful.”  —Pharma/Biotech Respondent
    • “We outsource for capabilities we don’t have in-house.  Cost could be a factor; we want to make high quality protein, so it may be cheaper to outsource once we have a commercial product.  If we needed extra capacity we might outsource until we can build it in-house.”  —Pharma/Biotech Respondent
    • “We’re developing new drugs, so the first consideration is IP.  The second is experience.  Speed to clinic is a consideration in whether to outsource and that depends on the CMO having the necessary experience.  Many CMOs don’t have industrial experience and know-how for commercial.  The third is cost.”  —Pharma/Biotech Respondent
    • “Capacity, technical capabilities we don’t have internally (e.g., certain analytical testing technology), dual supply.  For late-stage products, another driver is strategic location to manufacture for certain markets and have a more easily managed supply chain.”  —Pharma/Biotech Respondent

    Cell and gene therapy outsourcing
    As mentioned previously, serving the cell and gene therapy market is a growth opportunity for CMOs. It is expected that cell and gene therapies will be a significant portion of the biopharmaceuticals entering the clinical pipeline in the near future. Along with these opportunities, cell and gene therapy production presents several challenges for CMOs. First, the production of cell and gene therapies differs from protein therapeutics. Manufacturing needs to be highly flexible to accommodate the small patient populations. The manufacturing processes require technology innovation and operational streamlining. Also, the industry currently lacks the capacity to support all the innovator companies entering this space. In addition, the respondents noted the need for improvements in cell technology such as increased cell viability, reproducibility, and stable cell lines. Other manufacturing hurdles are a) unclear regulations, b) scalability, and c) lack of manufacturing platform technology.

    Besides production issues, the complexity of supply chain logistics and distribution with a short turnaround time present a critical business challenge to the CMOs. Furthermore, there is the high cost of manufacturing cell and gene therapies because the cost is not optimized due to its small scale. Finally, because the field is relatively new with diverse technologies, it is a challenge to recruit capable personnel with expertise and build training.

    As with any new technology, there are plenty of exciting opportunities. The respondents expect innovations along with the application of existing technologies (e.g., automation, closed systems and disposable technologies) will help reduce manufacturing costs. In addition, the respondents believe that scale improvement through cell suspension process will increase batch size and reduce production costs. Furthermore, the development of off-the-shelf product (i.e., allogenic cell bank for multi patients) will help commoditize the process. Finally, because cell and gene therapy activities are currently fragmented and only a few CMOs have cell and gene therapy capabilities, there exists growth opportunities for CMOs. This is especially true for those CMOs able to provide full integrated services.

    Overall industry trends
    The biomanufacturing directors at pharmaceutical and biotechnology companies discussed biopharmaceutical contract manufacturing industry trends. Most respondents expect continuing industry growth. Some of the reasons for their assessment are a) the increase in the biopharmaceutical pipeline, b) the growth in cell and gene therapies, and c) the increase in small biotechnology companies with no in-house manufacturing.

    Another reason for continuing industry growth is the use of CMOs by large pharmaceutical and biotechnology companies to meet variable demand and gain access to other capabilities. Other trends mentioned by the respondents include continuing industry consolidation. They also expect new CMOs to enter the market, and they expect CMOs to become more specialized. This specialization means CMOs may focus on certain product phase, customer size or technologies. Finally, the respondents noted the need for flexible manufacturing as more therapeutics are developed that target smaller patient populations. They anticipate CMOs will adopt new process technologies to help solve some of the challenges of managing multiple products requiring rapid changeovers to support faster timelines.

    Closing
    Both the supply and demand for biopharmaceutical contract manufacturing services have grown over the past three years. In response to the higher demand, the CMOs have added new capacity, and they will continue to invest in new capacity and new capabilities to support their customers’ growth plans. From our analysis, we expect the market will reach $6.3 billion in 2020, and it will continue to grow at robust rates over the next five years. 

    References
    1. http://www.hightechdecisions.com/reports.html


    William Downey is the president of HighTech Business Decisions, a market research and consulting company that has been publishing reports on the biopharmaceutical contract manufacturing market since 1997. For more information, visit www.hightechdecisions.com or call (408) 978-1035.
    Related Searches
    • Biologics, Proteins, Vaccines
    • Drug Development
    • Biosimilars

    Related Features

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20

    • Biosimilars
      Biosimilar Manufacturing Strategies

      Biosimilar Manufacturing Strategies

      Five steps to competing in a post-patent expiry era.
      George I’ons, Owen Mumford Pharmaceutical Services 09.09.20

    • Drug Development | Preclinical Outsourcing
      Preclinical Planning for Successful Drug Development

      Preclinical Planning for Successful Drug Development

      When the preclinical pressure is on, appropriate planning can make sure timelines are achievable.
      Mingyi Trimble, WuXi AppTec 09.09.20


    • APIs | Drug Development | Risk Management
      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-molecule drug development has become more complex and challenging, leading to greater reliance on CDMOs.
      Sarah Bethune, Cambrex 09.09.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Biologics, Proteins, Vaccines
      CAR-T Cell Therapy in Clinical Trials

      CAR-T Cell Therapy in Clinical Trials

      The importance of CAR-T cell therapy in clinical trials: the industry’s evolving, maturing focus
      Panteli Theocharous, Cell and Gene Therapy Strategy Lead, PPD 06.04.20


    • Biologics, Proteins, Vaccines
      Cell Therapy Manufacturing

      Cell Therapy Manufacturing

      Addressing the growing pains in cell therapy manufacturing
      Dr. Alessandra De Riva, Director of Process Development, Mogrify Ltd. 06.04.20

    • Biologics, Proteins, Vaccines
      The New Wave of Innovation

      The New Wave of Innovation

      Cell and gene therapies represent the new wave of innovation in the life sciences industry
      Tim Wright, Editor, Contract Pharma 06.04.20

    • Biosimilars
      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      Biosimilar uptake set to reshape the U.S. market
      Katya Svoboda and Bob Swann, ICON 05.05.20


    • Biologics, Proteins, Vaccines
      CEO Spotlight: Dr. Tae Han Kim

      CEO Spotlight: Dr. Tae Han Kim

      Samsung Biologics’ chief executive talks biopharma outsourcing trends, company growth initiatives and the impact of the coronavirus pandemic
      Tim Wright, Editor, Contract Pharma 05.05.20

    • Biologics, Proteins, Vaccines
      Covid 19: Impact on Bioprocessing and Outsourcing

      Covid 19: Impact on Bioprocessing and Outsourcing

      Outsourcing of biologics is increasing due to Covid-19, but what will change in the long-run?
      Ronald A. Rader & Eric S. Langer, BioPlan Associates 05.05.20

    • Biologics, Proteins, Vaccines
      The Evolution of the ADC Manufacturer

      The Evolution of the ADC Manufacturer

      How CMDOs can rise to the occasion
      Lisa McDermott and Jyothi Swamy, MilliporeSigma 04.01.20

    Trending
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Bormioli Opens New Glass Research Center
    • WuXi AppTec Completes OXGENE Acquisition
    • Arcline Investment Acquires ChargePoint Technology
    Breaking News
    • Fusion Pharmaceuticals Acquires IPN-1087
    • Strata Oncology Unveils Strata PATH Trial
    • Alimentiv Acquires McDougall Scientific
    • Q BioMed Inks Strontium89 Supply Pact
    • PCI Pharma Services Appoints SVP, CFO
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Low Levels of Vitamin D and Calcium Linked to COVID-19 Severity
    Probiotic Evidenced to Assist Digestive Recovery from a Complex Surgery
    AHPA Submits Comments to FDA on Proposed Traceability Rule
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    AOC Announces EMEA Price Increase
    Mule-Hide Products Co. Introduces Seal-Fast Liqui-Flash
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    NAMSA Acquires American Preclinical Services
    Quidel's QuickVue At-Home COVID-19 Test Earns EUA
    Memic Receives FDA Marketing Authorization for Hominis
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Fusion Pharmaceuticals Acquires IPN-1087
    Strata Oncology Unveils Strata PATH Trial
    Alimentiv Acquires McDougall Scientific
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    IT Cosmetics Supports Women’s Confidence
    Inter Parfums Reports a Strong Fourth Quarter
    Universal Engraving Announces New President
    Happi

    Latest Breaking News From Happi

    Croda International Acquires Alban Muller
    Givaudan Active Beauty Launches Omegablue
    Sozio Acquires Scentessence
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Abbott Label installs Domino K600i dual bar digital UV inkjet printer
    Crossmark turns to Eagle Systems for cold foil
    Maxcess launches Tidland PressureMax Airshaft Pressure Monitoring System
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Domtar Completes Sale of Personal Care Business
    Mitsui to Sell Chinese Nonwovens Business
    Dr. J's Disinfectant Wipes Approved for Distribution in CA
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    SeaSpine Releases Reef TO (TLIF Oblique) Interbody System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login